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Objective: Abrupt increases in right ventricular afterload occur after cardiac trans-
plantation and pulmonary artery banding, which can result in right ventricular
hypertrophy and dilatation. Right ventricular dysfunction is also accompanied by
-adrenergic receptor desensitization. We sought to determine whether selective
right ventricular expression of a transgene encoding a -adrenergic receptor kinase
inhibitor can improve right ventricular remodeling early after pulmonary artery
banding.
Methods: Rabbits underwent pulmonary artery banding 3 days after percutane-
ous right coronary artery injection of empty adenovirus (n  19), a control
adenovirus containing the -galactosidase transgene (n  10), or an adenovirus
containing the -adrenergic receptor kinase inhibitor transgene (n  14).
Sham-operated animals (n  7) underwent instrumentation without deployment
of the pulmonary artery band. Right ventricular function was assessed in each
rabbit before and 7 days after pulmonary artery banding. Right ventricular mass
and dimensions (surface area and volume) were obtained, and biochemical
analysis was performed to confirm transgene expression and to characterize
-adrenergic receptor signaling.
Results: Right ventricular mass was increased in animals treated with adenovirus
containing the -adrenergic receptor kinase inhibitor transgene, adenovirus contain-
ing the -galactosidase transgene, and empty adenovirus after banding when com-
pared with results in sham-operated animals. However, right ventricular volume and
surface area, as measures of dilatation, were significantly lower in pulmonary artery
banded rabbits pretreated with adenovirus containing the -adrenergic receptor
kinase inhibitor transgene when compared with those treated with empty adenovirus
or adenovirus containing the -galactosidase transgene. Right ventricular contrac-
tility and defective -adrenergic receptor signaling were significantly enhanced in
rabbits expressing the -adrenergic receptor kinase inhibitor after pulmonary artery
banding.
Conclusions: Right ventricular preconditioning with the -adrenergic receptor ki-
nase inhibitor transgene can attenuate the early right ventricular dilatation and
dysfunction associated with pulmonary artery banding. Thus -adrenergic receptor
kinase inhibition might represent a novel target for limiting ventricular remodeling
after increased right ventricular afterload.
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Increased right ventricular (RV) afterload might oc-cur after cardiac transplantation and certain proce-dures in congenital heart surgery.1,2 Acute RV fail-ure in the postoperative setting could carry up to70% mortality despite aggressive management be-cause of the inability of the right ventricle to ade-
quately compensate for the increased afterload.3,4 One
model of increased RV afterload is pulmonary artery (PA)
banding. In this model RV hypertrophy and dilatation occur
early and are followed by an eventual impairment in RV
contractility.5,6 Biochemical abnormalities in hypertrophy
and ventricular dysfunction include those of the -adrener-
gic receptor (AR) signaling system. Increased levels of the
AR kinase (ARK1) can lead to enhanced receptor phos-
phorylation and desensitization.7-10
Several studies in genetically engineered mice have pro-
vided evidence that increased myocardial ARK1 might be
involved in the pathogenesis of ventricular failure, and
accordingly, a potential therapeutic strategy for the treat-
ment of heart dysfunction is the inhibition of ARK1.11 The
ARKct is a 194-amino-acid peptide corresponding to the
carboxyl terminus of ARK1, which competes with
ARK1 for receptor binding sites and thus inhibits its
activity. Studies in mice and rabbits have shown that car-
diac-targeted expression of ARKct leads to enhanced left
ventricular (LV) functional performance.12-17 However, no
study has evaluated the effects of ARKct gene transfer on
ventricular function in an animal model of increased ven-
tricular afterload. Furthermore, the effects have not been
evaluated in the setting of RV dysfunction. In the present
study we examine the effects of intracoronary adenoviral-
mediated gene transfer of the ARKct to the RV before PA
banding on ventricular remodeling and dysfunction.
Methods
Adenoviral Constructs and Experimental Groups
The adenovirus backbone for the ARKct transgene (Adeno-
ARKct) and the control empty adenovirus (EV) is a second-
generation adenovirus with deletions of the E1 and E4.16,18 A
second control virus containing the gene encoding -galactosidase
(Gal) was constructed by using a first-generation adenovirus.19
New Zealand White rabbits (2.5 kg) were randomly assigned to
receive control EV (n  19), adenovirus containing the -galac-
tosidase transgene (Adeno-Gal; n 10), or Adeno-ARKct (n
14). A separate group of sham-operated animals (n  7) did not
undergo either gene transfer or PA band deployment. All animals
were treated in accordance with guidelines published by the Na-
tional Institutes of Health (publication no. 86-23, revised 1985).
PA Band Placement and In Vivo Intracoronary Gene
Delivery
Before gene delivery, rabbits underwent placement of a deployable
PA band. After achievement of general anesthesia (inhaled isoflu-
rane), the PA was isolated through a left thoracotomy. A band,
consisting of a 2  10–mm strip of reinforced silicone rubber
(Silastic) with 2-0 silk suture tails at both ends, was positioned
with the strip loosely encircling, but not compressing, the PA. The
tails of the band apparatus were passed through a Silastic tube,
externalized from the thoracic cavity, and placed in a subcutaneous
pocket to allow access for subsequent band deployment. After
recovery (2-4 days), rabbits received selective infusion of adeno-
virus into the right coronary artery (RCA), which was performed
as previously described.19 Briefly, after achievement of light se-
dation (55 mg/kg ketamine administered intramuscularly) and lo-
cal anesthesia (1% lidocaine), the left carotid artery was isolated.
A 3.0F angle-tipped catheter (Cook) was advanced intraluminally
into the RCA under fluoroscopic guidance.19 Sham-operated ani-
mals underwent sedation and catheterization without gene deliv-
ery.
PA Band Deployment
After gene delivery, rabbits were recovered for 4 days to allow for
transgene expression and then underwent PA band deployment.
During light sedation and local anesthesia, a right cervical incision
was made, and a 2.5F micromanometer (Millar Instruments) was
introduced into the jugular vein and advanced into the right ven-
tricle to measure RV pressures.19 A separate incision was made on
the left chest wall over the subcutaneous pocket containing the
tails of the PA band. The band was deployed by advancing the
Silastic tube over the suture tails, leading to external compression
of the PA. The internal diameter of the band after deployment is
3.2 mm. Successful band deployment was confirmed by observing
an increase in RV pressures. Sham-operated animals underwent
sedation and catheterization without band deployment. The sur-
geon performing the band deployment procedure was blinded to
the treatment status (ie, Adeno-ARKct, Adeno-Gal, or EV) of
each animal. After 30 minutes of monitoring, RV mean ejection
pressure and dP/dtmax were recorded.
Determination of RV Volume, Mass, and Surface Area
After 7 days, repeat RV hemodynamic measurements were ob-
tained by means of jugular vein cutdown and micromanometry.
Animals were killed by means of intravenous injection of 20 mEq
of KCl, and hearts were harvested. The RV free wall was excised
from the heart, and ventricular masses were obtained. RV free wall
surface area was measured by means of planimetry.16 In a subset
of animals (n  5, Adeno-ARKct; n  5, EV; and n  5, sham),
unstressed intraventricular RV volumes were measured before RV
dissection by using the following technique. Harvested hearts were
placed in 4°C cardioplegia solution, and atria were ligated at the
atrioventricular groove. Cannulae were inserted retrograde through
the PA and aorta into the RV and LV chambers and secured in
place with external ties. RV intraventricular volume (at 5 mm Hg)
was measured by pressurizing the left ventricle to 10 mm Hg and
infusing normal saline solution into the right ventricle until the
intraventricular pressure reached 5 mm Hg. The volume of infusate
was determined to be the unstressed RV volume (at 5 mm Hg).
Volume measurement was repeated 3 times in each heart, and the
mean value of these measurements was documented. Echocardi-
ography (subxyphoid approach, variable 5-12 MHz probe) with
color Doppler flow analysis was used to estimate the peak pressure
gradient across the PA band.
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Confirmation of Transgene Expression
To detect the presence of ARKct mRNA, Northern blot analysis
was performed on RV and LV samples from ARKct-treated,
EV-treated, and sham-operated animals, as described previously.16
Gal staining was performed on ventricular samples from animals
treated with the Adeno-Gal transgene.19
Myocardial AR Density and Signaling
Membranes were prepared, and total AR density was determined
by means of radioligand binding with a saturating concentration
(300 pmol/L) of iodine 125–labeled cyanopindolol at 37°C for 1
hour.16,17 To measure membrane adenylyl cyclase activity, 20 g
of myocardial membrane protein was incubated with 0.1 mol/L
[-32] adenosine triphosphate for 15 minutes at 37°C under basal
conditions or in the presence of 1 mmol/L isoproterenol or 10
mmol/L sodium fluoride, and cyclic adenosine monophosphate
(cAMP) production was quantified by using standard methods.16,17
Myocardial ARK1 levels were detected by means of immuno-
blotting for ARK1, as previously described.9,20
Statistical Analysis
Actual survival after 7 days of PA banding in each group was
compared, and a 2 test was performed to determine statistical
significance. Hemodynamic and geometric parameters were com-
pared by means of analysis of variance and are expressed as means
 SE. The post hoc Sheffe subgroup test was performed to
compare individual groups if statistical significance was achieved
by using analysis of variance. A Student t test was used to compare
adenylyl cyclase activities between groups.
Results
RV–Targeted Transgene Delivery
Northern blot analysis was performed to detect ARKct
transgene expression in ventricular samples from treated
rabbits. ARKct mRNA expression is RV specific and is
seen only in the Adeno-ARKct–treated animals (Figure 1,
A). The distribution of Gal expression in the RV and
septum (Figure 1, B) is consistent with previous data on
subselective coronary artery catheterization and adenovirus
injection into the rabbit heart.19
PA Banding, Hypertrophy, and Survival
All rabbits used had similar body weights (Table 1). The
mean peak pressure gradient across the PA band, as mea-
sured by means of Doppler imaging, did not differ signifi-
cantly between animals pretreated with Adeno-ARKct or
EV (23  7 vs 20  5 mm Hg, P  not significant) after 7
days of banding. Rabbits pretreated with control viruses or
Adeno-ARKct had higher RV masses after PA banding
when compared with sham-operated control animals, but
LV mass was similar among groups (Table 1). We found a
significant difference in 7-day survival when rabbits pre-
treated with control adenovirus were compared with those
treated with Adeno-ARKct (14/29 [48%] vs 13/14 [93%],
respectively; P  .01, 2 test; Table 1). At the time of
necropsy, surgical complications, such as arterial rupture,
band migration, and infection, were excluded as causes of
death. Animals that died appeared to have RV dilatation,
mild bilateral pleural effusions, and, occasionally, ascites.
Physiologic Effects of ARKct Expression on PA
Banding
Mean hemodynamic parameters measured at the time of PA
banding are presented in Table 1. Measurements were taken
before and immediately after band deployment. There were
no significant differences in heart rate between the control
(EV and Gal) and Adeno-ARKct–treated groups at either
time point (Table 1). RV peak systolic blood pressure and
end-diastolic pressure increased appropriately after PA
banding, but there were no differences between groups
(Table 1). RV dP/dtmax, as a measure of ventricular con-
tractility, was similar in all groups before band deployment
but was significantly higher after PA banding in rabbits
pretreated with Adeno-ARKct compared with values in
rabbits treated with control viruses or sham-operated rabbits
(P  .05).
Unstressed RV volume was significantly lower in Ad-
eno-ARKct–treated rabbits compared with in EV-treated
animals but was lowest in sham-operated animals (Table 1).
We also assessed RV dilatation by measuring unstressed
ventricular free wall surface area by means of planimetry.
PA-banded rabbits pretreated with Adeno-ARKct had a
significantly lower mean surface area compared with those
pretreated with EV. Both of these values were higher than
the mean surface area measured in sham-operated control
animals (Table 1).
AR Signaling Effects of PA Banding and ARKct
Expression
To assess biochemical changes induced in the RV after PA
banding, we assessed AR density, ARK1 levels, and
adenylyl cyclase activity. Mean RV AR density was not
different between each group of animals (data not shown).
ARK1 levels were increased in ventricular samples from
PA-banded rabbits, and levels were higher in the right
ventricle compared with in the left ventricle of all banded
animals (Figure 2). Pretreatment with Adeno-ARKct be-
fore PA band deployment did not alter increased ARK1
levels after PA banding.
To investigate whether increased ARK1 affected AR
signaling, we measured adenylyl cyclase activity in mem-
branes prepared from the various right ventricles. As shown
in Figure 3, PA banding did result in decreased basal,
isoproterenol-mediated, and sodium fluoride–mediated
cAMP production. However, these were normalized in the
Adeno-ARKct–treated rabbits. In terms of AR respon-
siveness (isoproterenol stimulation over basal cAMP),
banded values (20%  4%, n  4) were significantly
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decreased compared with sham values (43% 11%, n  4,
P  .05), whereas ARKct restored this response (53% 
10%, n  4, P  .05 vs banded).
Discussion
The present study demonstrates that RV-specific, adeno-
viral-mediated gene transfer of the ARKct peptide in a
model of acute ventricular pressure overload can signif-
icantly alter the course of early RV dysfunction. We
targeted ARK1 activity because this kinase appears to
be involved in the pathogenesis of ventricular dysfunc-
tion and heart failure.11 Selective RV expression of the
ARKct, which inhibits ARK1 through competition for
G binding and membrane translocation,12 was accom-
plished by means of percutaneous, catheter-mediated
RCA injection of Adeno-ARKct. Importantly, we found
that RV-specific ARKct expression before PA banding
limits RV dilatation and improves contractility and sur-
vival early in the course of ventricular remodeling. The
physiologic changes were associated with near normal-
ization of intracellular AR signaling, suggesting func-
tionality of the ARKct transgene.
A
B
Figure 1. A, ARKct transgene expression after RCA adenovirus delivery. RV-specific ARKct mRNA expression
was confirmed by means of Northern blot analysis of total RNA isolated from the RV and LV of 2 separate (a and
b) Adeno-ARKct–treated rabbits while absent from an Adeno-Gal–treated animal. B, Representative Xgal
staining of a cross-section obtained from a banded animal pretreated with Adeno-Gal. (Original magnification
4.)
Cardiopulmonary Support and Physiology Emani et al
790 The Journal of Thoracic and Cardiovascular Surgery ● March 2004
CSP
PA banding in rabbits is a model of severe right-heart
failure leading to early RV dysfunction and mortality.
Seven days after PA banding, the increased afterload placed
on the right ventricle resulted in a near doubling of the RV
mass and volume. The surface area of the right ventricle was
also significantly increased 7 days after PA banding. More-
over, PA banding was accompanied by a high mortality in
rabbits that received the control EV. This model was used
for several reasons. First, the time course and severity of RV
dysfunction is reproducible and resembles the early RV
failure seen in clinical settings of acute pressure overload.
Second, the degree of banding achieved was similar in each
animal because the band diameter was constant and animal
size was similar between groups, thus decreasing variability
in PA size.
The beneficial effects of ARKct on RV dysfunction
after PA banding is consistent with previous studies that
have demonstrated the benefits of ARK1 inhibition in
other models of heart failure. Transgenic mice with cardiac
ARKct expression have enhanced cardiac function12 that
is preserved in LV pressure overload hypertrophy,9 and
concurrent ARKct expression has shown benefit in several
murine models of heart failure.13-15 In addition to these
mouse studies, Adeno-ARKct has also led to positive
effects in a rabbit model of LV dysfunction after myocardial
infarction.16,17 The present study differs from previous stud-
ies in several important ways. First, in addition to showing
improvement in contractility, we demonstrate a favorable
effect of ARK inhibition on early ventricular dilatation,
which has not been previously described. Second, whereas
previous studies have focused on treatment of LV dysfunc-
tion, the potential benefit of ARKct has now been shown
specifically for RV dysfunction in the setting of acute pres-
sure overload. Finally, the therapeutic strategy used in this
study was pretreatment of the right ventricle by means of
gene transfer several days before imposition of the in-
creased afterload, thus allowing an adequate interval for
ARKct expression. This strategy of genetic precondition-
ing through RCA-mediated ARKct injection might be
useful in appropriate clinical settings, such as before
planned surgical procedures in which increased RV after-
load is anticipated.
The fact that hypertrophy was not prevented by ARKct
expression is not surprising because a previous study in
mice has shown that the hypertrophic response in the left
ventricle after aortic constriction was not altered by myo-
cardial-targeted ARKct expression.9 However, the
ARKct did restore ventricular dysfunction associated with
pressure-overload hypertrophy,9 which is consistent with
our findings in the present study showing improvement in
RV contractility in Adeno-ARKct–treated rabbits after PA
banding. We have previously shown that ARK1 is upregu-
lated in certain forms of hypertrophy, including LV pressure
overload and RV volume overload, and that increased de-
sensitization is responsible for AR uncoupling and not
AR downregulation.9,10,20 Similarly, in this study we
found that RV pressure overload in the rabbit is associated
with ARK1 upregulation, which is not reversed by
ARKct expression. Importantly, although expression of
the ARKct does not alter the increased ARK1 expres-
sion, it apparently can block any enhanced activity of this
upregulated kinase, as evidenced by normalization of ad-
enylyl cyclase activity in banded animals treated with Ad-
eno-ARKct.
The distribution of transgene expression is consistent
with previous experience using subselective RCA injection.
Gal expression was seen in the RV free wall and interven-
tricular septum, and ARKct mRNA was demonstrated
only in RV samples. ARKct transgene expression was
inferred from the presence of mRNA and evidence of down-
stream biochemical activity (restoration of adenylyl cyclase
activity).
Ventricular contractility was assessed by using microma-
nometry to derive dP/dtmax and global hemodynamics.
DP/dt is a crude measure of contractility because it is both
preload and afterload dependent. Although preload-inde-
pendent measures of RV function are more sensitive than
dP/dt, techniques used to obtain these measurements (con-
ductance catheter, magnetic resonance imaging, and ultra-








BW (kg) 2.6 0.3 2.5 0.2 2.6 0.2
HR (beats/min)
Before banding 189 19 194 31 177 23
After banding 194 28 203 38 188 32
SBP (mm Hg)
Before banding 17.6 2.4 18.4 3.2 16.3 1.7
After banding 34.7 7.1*‡ 32.1 5.9*‡ 15.7 2.2
EDP (mm Hg)
Before banding 2.2 0.41 1.9 0.52 2.1 0.36
After banding 3.3 0.63‡ 3.4 0.62*‡ 2.3 0.31
dP/dtmax (mm Hg/s)
Before banding 447 31 439 34 431 29
After banding 653 51*†‡ 539 45*‡ 425 30
7-d survival 92.8%† 48.3% 100%
LV mass (g)§ 3.56 0.23 3.62 0.31 3.52 0.18
RV mass (g)§ 1.8 0.13‡ 1.8 0.10‡ 0.94 0.09
RV surface area (cm2)§ 5.9 0.28†‡ 7.1 0.33‡ 4.9 0.12
RV volume (cm3) 1.9 0.30†‡ 2.9 0.40‡ 1.3 0.20
BW, Body weight; HR, heart rate; SBP, systolic blood pressure; EDP,
end-diastolic pressure.
*P  .05, after banding versus before banding.
†P  .05, versus EV/Gal.
‡P  .05, versus sham.
§ARKct, n  13; EV, n  10; sham, n  7.
ARKct, n  5; EV/Gal, n  5; sham, n  5.
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sonic transducers) are unreliable when applied to the right
ventricles of small animals. Despite the relative lack of
sensitivity of dP/dt, we were able to detect a significant
difference between the control and treated groups.
Although ventricular dilatation was attenuated in
ARKct–expressing animals, unstressed RV volume and
free wall surface area did not completely normalize when
compared with that of sham-operated animals. The exact
mechanisms contributing to ventricular dilatation are poorly
understood but are thought to include myocyte slippage,
elongation of the cardiac cell, extracellular matrix remod-
eling, myocyte dropout, and altered intracellular signaling
pathways.21,22 A plausible mechanism by which ARKct
prevents ventricular dilatation is by altering G protein–
coupled receptor signaling pathways (including ARs) ei-
ther due directly to ARK1 inhibition or possibly additional
pathways involving G-mediated signaling, which is an
alternative mechanism of ARKct action.11 Importantly,
some extracellular contributions to ventricular dilatation
(myocyte slippage and extracellular matrix remodeling) are
less likely to be affected by ARKct, which is consistent
with our finding that RV dilatation was not completely
inhibited by Adeno-ARKct treatment.
One limitation of the study arises from the difference in
mortality between the control and treatment groups. Nec-
ropsy was performed on all early fatalities, and evidence of
massive ventricular dilatation and right heart failure (ascites
and peripheral edema) was seen almost universally. Because
the values of RV dimensions and hemodynamics in the
control group might be underestimated, the differences be-
tween the Adeno-ARKct and control groups might also be
underestimated.
Another limitation of the current study is the acute win-
dow of observation. Accordingly, the long-term effects of
ARKct expression on ventricular performance in the set-
ting of chronically increased RV afterload were not appar-
ent. Nevertheless, we did find significant attenuation of RV
remodeling and dysfunction 7 days after PA banding, dem-
onstrating the benefits of genetic preconditioning on the
early phase of acute pressure overload. In clinical situations
such as cardiac transplantation, RV dysfunction is a major
cause of acute graft failure in the immediate postoperative
period.1,2 Such dysfunction is often refractory to adminis-
tration of systemic inotropic agents.3,4 Patients with post-
operative refractory acute RV failure rarely require ex-
tended mechanical support, with the duration of support
ranging from 2 hours to 8 days.3 Thus pretreatment of the
right ventricle with ARKct, even if expression is transient,
might be adequate for temporary RV support immediately
after imposition of increased afterload.
We thank K. Wilson and S. Duncan for excellent technical
assistance and the Genzyme Corporation (Framingham, Mass) for
Figure 2. ARK1 protein levels in ventricular samples. ARK1 content was visualized by means of Western
blotting after immunoprecipitation with a monoclonal antibody, as described previously.9,20 Shown is a represen-
tative blot for ventricular (RV and LV) ARK1 levels in listed animals.
Figure 3. RV membrane adenylyl cyclase activity. Basal, isopro-
terenol (ISO)–stimulated, and NaF-stimulated activities were all
reduced after PA banding (EV treated) compared with sham
values and normalized with Adeno-ARKct treatment. Data
shown are the means  SEM of 4 experiments, each done in
triplicate. *P < .05 versus sham; #P < .05 versus banded.
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